SCN2A-related Neurodevelopmental Disorder
Main Features
SCN2A-related neurodevelopmental disorder (SCN2A-NDD) is caused by pathogenic variants in SCN2A, which encodes the alpha subunit of the voltage-gated sodium channel Nav1.2 — critical for generating neuronal action potentials throughout the central nervous system. SCN2A is considered one of the highest-confidence single-gene causes of autism spectrum disorder and is among the more commonly identified monogenic causes of neonatal-onset epilepsy.
- Epilepsy
- Seizure type and severity vary by phenotypic subgroup, ranging from benign familial infantile seizures to severe developmental and epileptic encephalopathies (e.g., Ohtahara syndrome, infantile spasms, epilepsy of infancy with migrating focal seizures, Lennox-Gastaut syndrome)
- Developmental delay
- Intellectual disability present in over 90% of individuals in large cohorts
- Autism spectrum disorder (29% > than 2 years)
- Movement disorders
- Including dystonia, chorea, dyskinesia, stereotypies, episodic ataxia, and choreoathetosis
- Hypotonia (68%)
Phenotypic subgroups are recognized based on age of seizure onset and variant function:
- Early-onset (EO) epilepsy
- Late-onset (LO) phenotypes (seizure onset ≥3 months or no epilepsy): Typically caused by loss-of-function (LoF) variants. Includes late-onset epilepsy with mid-infancy onset (often infantile spasms), late-onset epilepsy with childhood onset, and ID/ASD without epilepsy. Sodium channel blockers are rarely effective and may worsen seizures.
Developmental outcomes vary widely. In a cohort of 100 individuals, 62% could sit independently, 55% could walk, and only 31% spoke more than 1–5 single words. Adaptive behavior composite scores on the Vineland Adaptive Behavior Scales were generally low across all subgroups.
Eye Findings
Visual and ocular abnormalities are common in SCN2A-NDD and are increasingly recognized as a core feature rather than an incidental finding.
- Cortical/cerebral visual impairment (CVI) (~40-45%)
- The most clinically significant ocular finding, reflecting impaired visual processing in the brain rather than a structural eye problem. Most common in neonatal-onset and infantile-onset phenotypic groups, decreasing in frequency in later-onset and ASD/ID groups.
- Broader visual problems (including visuomotor, depth perception, and distance-related difficulties) reported in a majority of affected individuals in emerging research cohorts
- Strabismus
- Reported in multiple cohorts; Howell et al. identified strabismus in 4 of 17 patients with SCN2A encephalopathy
- Nystagmus
- Refractive errors (myopia, hyperopia, astigmatism)
- Reduced visual acuity
- Optic atrophy
- Reported in individual cases. Baasch et al. described a patient with a de novo SCN2A missense mutation (p.R1882L) presenting with intractable seizures, severe intellectual disability, and optic atrophy alongside brain abnormalities and muscular hypotonia
- Oculogyric crises
- Paroxysmal conjugate tonic deviation of the eyes, typically upward, noted as part of the movement disorder spectrum in SCN2A-related disorders
Biological basis for visual involvement: NaV1.2 (encoded by SCN2A) is expressed in the retina, where it is found in retinal ganglion cell axons and in a subset of ON cone bipolar cells. In retinal ganglion cells, NaV1.2 is essential for action potential initiation and regeneration, and its expression is predominantly localized to intraretinal axons.[2][8] In bipolar cells, NaV1.2 may serve to amplify neurotransmitter release during rapid depolarization, thereby accelerating light responses.[7] NaV1.2 is also expressed in horizontal cells and amacrine cell processes within the inner plexiform layer.[1][9] This widespread retinal expression of NaV1.2 provides a plausible biological mechanism for the visual dysfunction observed in SCN2A-related disorders, potentially affecting both retinal signal processing and optic nerve function.
Other Findings
Beyond epilepsy, developmental disability, and eye findings, SCN2A-related disorders are associated with a range of additional clinical features:
Neurological
- Movement disorders: dystonia, chorea, dyskinesia, stereotypies, choreoathetosis (especially in LO-MI subgroup), and episodic ataxia
- Spasticity (reported in ~22% of individuals)
- Acquired microcephaly
- Structural brain abnormalities: cerebral atrophy, hypoplastic corpus callosum, and cortical dysplasia
- Malformation of cortical development has been described in association with specific GoF variants
Gastrointestinal
- Constipation, gastroesophageal reflux, chronic diarrhea
- Feeding difficulties requiring nasogastric or gastrostomy tube (22% requiring G-tube for most or all nutrition)
Musculoskeletal
- Scoliosis (reported in 22%)
- Orthopedic issues related to hypotonia or movement disorder
Respiratory/Autonomic
- Episodic hyperventilation, breath-holding spells
- Autonomic dysfunction (tachycardia, temperature instability)
Behavioral/Psychiatric/Other
- Extreme irritability
- Auditory startle
- Sleep disturbances
- Speech and language impairment
- Behavioral and sensory processing differences, including atypical responses to sensory stimuli
- Vulnerability to secondary psychiatric disorders including bipolar disorder in adults with SCN2A-related ASD
Dysmorphic features
No specific facial gestalt is recognized, although dysmorphic features were noted in approximately 27% of patients in one cohort
Etiology
SCN2A-related neurodevelopmental disorder (OMIM #182390) follows an autosomal dominant inheritance pattern. The vast majority of pathogenic variants causing severe phenotypes arise de novo (i.e., are not inherited from parents), while inherited variants are more commonly associated with the milder, self-limited epilepsy phenotypes.[2][4]
The SCN2A gene is located on chromosome 2q24.3 and encodes the NaV1.2 voltage-gated sodium channel alpha subunit, expressed throughout excitatory neurons of the central nervous system. The channel consists of four homologous domains, each with six transmembrane segments. The S4 segment acts as the voltage sensor, and the S5–S6 segments form the ion selectivity pore.[4]
Variant types and functional consequences
- Gain-of-function (GoF) variants: Typically missense mutations that increase sodium channel activity and neuronal excitability through mechanisms such as slowing of fast inactivation, acceleration of recovery from inactivation, or increased persistent sodium current. Associated with early-onset (neonatal/infantile), often more severe, epileptic encephalopathies.
- Loss-of-function (LoF) variants: Include both missense and truncating (nonsense, frameshift) mutations that reduce NaV1.2 channel activity and neuronal excitability. Mechanisms include reduced protein expression (haploinsufficiency via nonsense-mediated decay), protein instability, depolarizing shift of voltage-dependent activation, or hyperpolarizing shift of channel availability. Associated with later-onset seizures (or no seizures), ID, and/or ASD. Sodium channel blockers are typically ineffective and may worsen seizures.
- 2q24.3 copy number variants (CNVs): Deletions encompassing SCN2A (and sometimes neighboring SCN1A and SCN3A) can also cause SCN2A-related phenotypes, often with severe developmental outcomes.
Patient-derived iPSC neurons have confirmed that LoF variants result in reduced NaV1.2 protein levels, decreased sodium current density, and impaired action potential firing, while GoF/epilepsy-associated variants show impaired sodium channel inactivation without changes in protein levels. This genotype-function-phenotype relationship is an active area of research and is beginning to guide precision treatment approaches, including selection of sodium-channel-targeted anti-seizure medications based on predicted variant function.
References
- Corradi A, Riva A, Sterlini B, et al. Functional Characterization of a De Novo SCN2A Mixed Variant Linked to [[https://www.openevidence.com/rare-disease/early-infantile-developmental-and-epileptic-encephalopathy|Early Infantile Developmental and Epileptic Encephalopathy. Neurol Genet. 2026;12(1):e200234]]